Download PDF
Nuklearmedizin 1998; 37(08): 297-298
DOI: 10.1055/s-0038-1632352
Originalarbeiten — Original Articles
Schattauer GmbH

Human Chorionic Gonadotropin and CA 15-3 Producing Adenocarcinoma

Human Chorionic Gonadotropin und das CA 15-3 produzierende Adenokarzinom der Lunge
G. Üçkaya
1   Department of Internal Disease, Gülhane Military Medical Academia, Ankara, Turkey
,
A. Özet
2   Department of Medical Oncology, Gülhane Military Medical Academia, Ankara, Turkey
,
A. Arpaci
2   Department of Medical Oncology, Gülhane Military Medical Academia, Ankara, Turkey
,
S. Kömiircü
2   Department of Medical Oncology, Gülhane Military Medical Academia, Ankara, Turkey
› Author Affiliations
Further Information

Publication History

Received: 01 October 1997

in revised form: 06 August 1998

Publication Date:
03 February 2018 (online)

Also available at
    Permissions and Reprints

Summary

50 years old man suffering from primary lung adenocarcinoma presented with high levels of both beta subunit human chorionic gonadotropin (βHCG) and cancer antigen 15-3 (CA 15-3) in the absence of elevated carcinoembrionic antigen (CEA), alfa fetoprotein (AFP) and carbohydrate antigen 19-9 (CA 19-9). Although βHCG or CA 15-3 high levels were reported in adenocarcinoma of lung, this is the first report of a patient with high levels of both markers.

Zusammenfassung

Im Blut eines 50jährigen Mannes, der an einem primären Adenokarzinom der Lunge litt, wurden hohe Werte für die Spiegel der beiden Sub- unit-Formen von Human Chorionic Gonadotropin (βHCG) und Krebsantigen 15-3 gefunden, während die Spiegel von CEA, AFP und CA 19-9 normal waren. Obwohl hohe Anteile an βHCG und an Ca 15-3 vorher bekannt waren handelt es sich um den ersten Bericht mit hohen Blutspiegeln für beide Krebsmarker.

Keywords

Lung cancer - tumor markers - βHCG - CA 15-3

Schlüsselwörter

Lungenkarzinom - Tumormarker - βHCG - CA 15-3
 

  • References

  • 1 DeVita Jr. VT, Hellman S, Rosenberg SA. Cancer principles and practice of oncology.. 5th ed. Philadelphia: Lippincott-Raven Publishers; 1997: 546-52.
  • 2 Jacobs EL, Haskell CM. Clinical use of tumor markers in oncology.. London: Blackwell Scientific Publications; 1992: 301-60.
  • 3 Klepp O, Romslo I. Tumor markers – an update: Proceeding from the first meeting on tumor markers. Trondheim. 1991: 8-105.
    PubMedGoogle Scholar
  • 4 Daar AS, Lennox ES. Tumor markers.. London: Blackwell Scientific Publications; 1987: 1-23.
  • 5 Fateh-Moghadam A, Stieber P. Sensible use of tumor markers.. Basel, Switzerland: Roch; 1993
  • 6 Kimura N, Ghandur-Mnaymen L. An Immunohistochemical study of keratin, carcinoembriyonic antigen, human chorionic gonadotropin and alpha-feto protein in lung cancer. Tohoku J. Exp Med 1985; 145: 23-38.
    CrossrefPubMedGoogle Scholar
  • 7 Nöda Y, Simodaira M, Ito H. Two cases of HCG producing large cell carcinoma accompanied with gynecomastia. Nippon Kyobu Gakkai. Zasshi 1990; 28: 781-5.
    Google Scholar
  • 8 Fukuda M, Sasaki Y, Morita M. Large cell carcinoma of the lung secreting HCG which responded to combination chemotherapy: case report. Jpn J Cli. Oncol 1990; 20: 299-305.
    Google Scholar
  • 9 Yoshimura M, Nishimura R, Murotani A. Assesment of urinary beta-core fragment of human chorionic gonadotropin as a new tumor marker of lung cancer. Cancer 1994; 73: 2745-52.
    CrossrefPubMedGoogle Scholar
  • 10 Huang SC, Hsieh CY, Hwang JL, Ouyang PC, Chen HC. Free alpha subunit of HCG in women with non-trophoblastic tumors. Taiwan I. Hsueh. Hui Tsa Chih 1989; 88: 218-25.
    Google Scholar
  • 11 Colomer R, Ruibal A, Genolla J, Salvador L. Circulating CA 15-3 levels in non-mammary malignencies. Br. J. Cancer 1989; 59: 283-6.
    CrossrefPubMedGoogle Scholar